BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 226 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q1 2021. The put-call ratio across all filers is 1.62 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $21,935,000 | -37.5% | 185,000 | -26.6% | 0.65% | -26.2% |
| Q4 2021 | $35,068,000 | -12.0% | 252,000 | -12.2% | 0.88% | -15.9% |
| Q3 2021 | $39,867,000 | +12.5% | 287,000 | -21.4% | 1.05% | +12.3% |
| Q2 2021 | $35,434,000 | +50.3% | 365,000 | +5.8% | 0.94% | +48.3% |
| Q1 2021 | $23,581,000 | -8.3% | 345,000 | +15.0% | 0.63% | -6.0% |
| Q4 2020 | $25,713,000 | -2.2% | 300,000 | -25.8% | 0.67% | -13.3% |
| Q3 2020 | $26,292,000 | -8.0% | 404,427 | +3.4% | 0.78% | -17.2% |
| Q2 2020 | $28,586,000 | +127.0% | 391,000 | +5.7% | 0.94% | +85.7% |
| Q1 2020 | $12,591,000 | -11.0% | 370,000 | +42.3% | 0.50% | +3.3% |
| Q4 2019 | $14,154,000 | +54.2% | 260,000 | +18.2% | 0.49% | +44.0% |
| Q3 2019 | $9,178,000 | +90.5% | 220,000 | +100.0% | 0.34% | +87.3% |
| Q2 2019 | $4,817,000 | – | 110,000 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 2,111,111 | $144,294,000 | 54.16% |
| Knoll Capital Management, LLC | 856,844 | $58,565,000 | 38.16% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,123,271 | $145,126,000 | 21.73% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 860,261 | $58,799,000 | 6.01% |
| ARS Investment Partners, LLC | 561,442 | $38,375,000 | 4.46% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $12,057,000 | 3.19% |
| Eventide Asset Management | 2,015,000 | $137,725,000 | 2.04% |
| Avidity Partners Management LP | 1,049,800 | $71,754,000 | 1.98% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 50,089 | $3,424,000 | 1.87% |
| Nicholas Investment Partners, LP | 375,654 | $25,676,000 | 1.79% |